Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese Han population

• Published in: Molecular carcinogenesis Vol. 51; no. S1; pp. E1 - E10
• Main Authors: Fan, Weiwei, Zhou, Keke, Hu, Dezhi, Song, Xiao, Zhao, Yingjie, Chen, Hongyan, Wei, Qingyi, Chen, Gong, Shi, Jinlong, Du, Guhong, Mao, Ying, Lu, Daru, Zhou, Liangfu
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.2012; Wiley Subscription Services, Inc
• Subjects: Adult; Asian Continental Ancestry Group - genetics; Brain tumors; Cancer; Case-Control Studies; Central Nervous System Neoplasms - genetics; China; cumulative effect; Enzymes; Female; Genetic Predisposition to Disease; genetic susceptibility; glioma; Glioma - genetics; Haplotypes - genetics; Humans; Male; Matrix Metalloproteinase 3 - genetics; Middle Aged; MMP3; Odds Ratio; Peptides; Polymorphism; Polymorphism, Single Nucleotide; Population genetics; Promoter Regions, Genetic; Risk Factors; China
• ISSN: 0899-1987; 1098-2744; 1098-2744
• DOI: 10.1002/mc.20842

Matrix metallopeptidases (MMPs) play an important role in central nervous system tumor growth, invasion and spreading. The currently available data provide clear evidence for the involvement of MMP3 in the pathophysiology of glioma. The study aims to explore the association of single nucleotide polymorphisms (SNPs) across the MMP3 gene with glioma risk. Three haplotype tagging and additional two promoter SNPs were genotyped among 766 glioma patients and 824 cancer‐free controls from East China. None of these polymorphisms alone had a significant effect on risk of gliomas. However, when three promoter polymorphisms were evaluated together by the number of putative risk of genotypes (i.e., rs645419AA, 632478CA+AA, rs522616AA), a statistically significantly increased risk of gliomas was associated with the combined genotypes with two to three risk genotypes, compared with those with zero to one risk genotypes (adjusted odds ratio (OR) = 1.32; 95% confidence interval (CI) = 1.03–1.68). This increased risk was also more pronounced among adults (adjusted OR = 1.14, 95%CI = 1.02–1.27), males (adjusted OR = 1.19, 95%CI = 1.05–1.36), smokers (adjusted OR = 1.28, 95%CI = 1.07–1.52), subjects with no family history of cancer (adjusted OR = 1.21, 95%CI = 1.07–1.37), and patients with nonastrocytic gliomas (adjusted OR = 1.23, 95%CI = 1.06–1.43). In summary, our results suggest that any one of MMP3 variants may not have a substantial effect on glioma risk, but a joint effect of MMP3 promoter polymorphisms may contribute to risk of gliomas, particularly for adult gliomas. © 2011 Wiley Periodicals, Inc.